Navigation Links
Lancet Oncology: Long-term side-effects of targeted therapies in pediatric cancer patients
Date:2/7/2013

A University of Colorado Cancer Center review published this week in the journal Lancet Oncology describes possible long-term side-effects of new, targeted therapies in pediatric cancer patients: what we don't know may hurt us.

"As pediatricians who treat kids with cancer, we expect the side-effects of traditional chemotherapies: low white blood count, infections, even long-term heart trouble or infertility. But there's the impression that these new, molecularly targeted agents are much less toxic. That may be true, especially in adult patients, but until we have more information about the long-term effects of these therapies in children, we need to be careful about how and when we prescribe them," says Chris Porter, MD, CU Cancer Center investigator and assistant professor of Pediatrics at the University of Colorado School of Medicine.

Already we know that molecularly targeted therapies may stunt the growth of pediatric patients, delay puberty or speed the onset of diabetes. And researchers are just now starting to ask about additional, sometimes unforeseen side-effects, potentially including more subtle issues such as neurocognitive, balance and motor defects.

"The growth of cancer cells isn't that different than the growth of a 7-pound baby into a 210-pound teenage linebacker. Now, you shut down these growth pathways in an adult and it might not be a big deal, but you shut down these same pathways at a critical time in childhood development and you can have real problems," says Lia Gore, MD, CU Cancer Center investigator and associate professor of Pediatrics and Medical Oncology at the CU School of Medicine.

The practical problem is this: FDA approval of many of these drugs for adult use allows physicians to prescribe the same drugs for pediatric use. Many are pills orally administered, outpatient treatments that make it difficult to recognize and track possible side-effects even in the short-term, let alone 10, 15 or 60 years later.

"The message I really want to convey is that our way of treating pediatric cancer has changed entirely in some diseases, and in some it's meant huge progress. A number of us have patients who have literally been cured by these new drugs. There are a lot of really cool therapies out there, but the issue is using them safely. With increased survival, we need to cure kids for 60-70 years. The question is how do we best treat these kids, knowing that cancer remains the enemy but you also don't want to induce complications that negatively affect the rest of their lives," Gore says.

"Personally, one of the most important things when choosing how to treat pediatric patients is to know what I don't know to acknowledge gaps in knowledge. Then as a researcher, we try to fill these gaps so that we can prescribe knowing the balance of risk and reward for these treatments," Porter says.

For now and until these questions are answered, the researchers recommend using molecularly targeted therapies with pediatric patients only in the context of a clinical trial. To Gore, Porter and co-author James DeGregori, PhD, the framework of a clinical trial provides the oversight needed for the rational prescription of these drugs in pediatric patients along with follow-up that includes more definite monitoring of side-effects than what Gore describes as "random use."

"One of the reasons we wrote this paper is that we don't understand the major risks, or even what the major risks might be," Porter says. "These targeted agents may affect the process of development in ways we can't predict."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Indias patent laws under pressure: The Lancet special report
2. Premier global health journal, The Lancet, releases series on universal health coverage
3. LTC Guild Member Releases Guidelines for Securing Long-Term Care Insurance for Parents
4. Prostate cancer study tracks long-term urinary, sexual and bowel function side effects
5. Long-term consequences of vaginal delivery on the pelvic floor
6. Study Links Long-Term Aspirin Use With Vision Loss
7. Gastric banding an effective long-term solution to obesity
8. USF and VA researchers find long-term consequences for those suffering traumatic brain injury
9. The Spencer Institute Supports New Year’s Resolutions and Long-Term Health with Wellness Coach Certification
10. Long-Term Aspirin Use Linked With Vision Loss: Study
11. Long-terms benefits follow brain surgery for certain forms of epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: